Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary B Gordon

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of the National Cancer Institute|December 1, 2010
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trialCraig A Elmets, Jaye L Viner, Alice P Pentland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignanciesKaren W L Yee, Anne Hagey, Srdan Verstovsek, et al.
Pharmacogenetics and Genomics|May 15, 2013
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751Federico Innocenti, Jacqueline Ramírez, Jennifer Obel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S Davids, Andrew W Roberts, John F Seymour, et al.
The Lancet. Oncology|January 17, 2017
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F Seymour, Shuo Ma, Danielle M Brander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent developmentJoyce A O'Shaughnessy, Gary J Kelloff, Gary B Gordon, et al.
The New England Journal of Medicine|September 1, 2006
Celecoxib for the prevention of sporadic colorectal adenomasMonica M Bertagnolli, Craig J Eagle, Ann G Zauber, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of the National Cancer Institute|December 1, 2010
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trialCraig A Elmets, Jaye L Viner, Alice P Pentland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignanciesKaren W L Yee, Anne Hagey, Srdan Verstovsek, et al.
Pharmacogenetics and Genomics|May 15, 2013
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751Federico Innocenti, Jacqueline Ramírez, Jennifer Obel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S Davids, Andrew W Roberts, John F Seymour, et al.
The Lancet. Oncology|January 17, 2017
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F Seymour, Shuo Ma, Danielle M Brander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent developmentJoyce A O'Shaughnessy, Gary J Kelloff, Gary B Gordon, et al.
The New England Journal of Medicine|September 1, 2006
Celecoxib for the prevention of sporadic colorectal adenomasMonica M Bertagnolli, Craig J Eagle, Ann G Zauber, et al.
Pageof 2